Bluejay Diagnostics reports Q2 EPS ($2.75) vs ($2.00) last year

Reports Q2 revenue $0 vs $249,040 last year. Cash and cash equivalents on June 30, 2023 were $5.1 million, as compared to $10.1 million on December 31, 2022. The Company closely monitors the management of its liquidity and expects to raise additional capital in the near-term to fund its planned operations. “We continued to limit our cash burn during the quarter while executing our clinical strategy for the Symphony IL-6 test and are confident that our planned clinical and analytical studies may support a 510k FDA regulatory submission with an initial indication for risk stratification of hospitalized sepsis patients,” said Neil Dey, CEO of Bluejay Diagnostics. “We are excited to now have a clear pathway to obtain regulatory clearance of our Symphony IL-6 test, which will serve to demonstrate the vast capabilities of our rapid, near-patient Symphony technology platform.”